source
- Amylyx's avexitide halves hypoglycemia episodes in phase 3 trial for post‑bariatric patientsAmylyx Pharmaceuticals reported that its GLP‑1 receptor antagonist avexitide significantly reduced dangerous blood‑sugar drops in a phase 3 study. The double‑blind Lucidity trial enrolled 78 indiv…
- EyePoint’s Phase 3 trial of duravyu fails to outperform aflibercept, shares plunge 70%EyePoint announced that its Phase 3 Lugano trial of the investigational tyrosine kinase inhibitor duravyu did not meet the primary efficacy endpoint when compared with the standard‑of‑care anti‑VEG…